Archive for the 'Pemetrexed (Alimta)' Category

Pemetrexed (Alimta) news feed.

Why is Chemotherapy Often Ineffective in Those Suffering from Mesothelioma?

Mesothelioma is a difficult cancer to treat for a multitude of reasons. A mesothelioma diagnosis is rare – only about 3,000 people per year in the United States are diagnosed – and this can make it difficult to study, given that there is generally a very small sample of patients that are able to be

more

ONCOS-102 Update: Mesothelioma Patients Responded after Phase II Clinical Trial

Advancement in mesothelioma treatments over the past decade has been relativity stagnant, according to Targovax  – a Norwegian immune-cology company dedicated to the study and research of immunotherapy treatments. However, those suffering from mesothelioma have hope, as continuing phases of clinical trials are showing positive results; the latest being ONCOS-12, an immunotherapy treatment that showed

more

Immunotherapy Treatment Durvalumab Enters Phase II Clinical Trial

While there is no cure for mesothelioma, those who are able to withstand surgery in general may have a better chance of survival, as the cancer is being physically removed. However, mesothelioma is a difficult cancer and often surgery is not an option, and the cancer is unresectable. The success of immunotherapy treatments for cancer

more

Effective Chemotherapy May Rest Upon Reducing Overactive Enzyme

Chemotherapy for mesothelioma patients has been notoriously difficult and the cancer continues to be overwhelmingly unresponsive to such treatment in many cases. However, researchers and scientists have been continually investigating new techniques that involve adjusting how chemotherapy reacts on a cellular level. A study published in the Frontiers in Pharmacology examines a specific enzyme that

more

ONCOS-102 Passes Safety Evaluation in Phase I Clinical Trials, Phase II Clinical Trial Recommended

A new immunotherapy developed by Targovax has recently passed Phase I clinical trials and is set to begin Phase II evaluation of this new treatment that may help those suffering from mesothelioma. ONCOS-102 was used in separate Phase I clinical trials; one in combination with chemotherapy, and one with immunotherapy. Cisplatin and pemetrexed are two

more

Bevacizumab – A Positive Treatment with Serious Side Effects

Bevacizumab (Avastin) is commonly viewed as chemotherapy treatment because when administered intravenously, it is particularly effective in controlling such illnesses such as lung cancer and colon cancer. However, it is a bit different than traditional chemotherapy treatments, which directly attack cancer cells. Bevacizumab fights cancer cells by cutting off oxygen and other nutrients the cells

more

The Effectiveness of Cisplatin and Pemetrexed in Pericardial Mesothelioma

Out of all the types of mesothelioma, pericardial mesothelioma is one of the rarest forms, accounting for only 0.002% of all known diagnosed mesothelioma cases. Mesothelioma is caused by asbestos exposure, and despite this knowledge and years of research, scientists and researchers still do not have a clear answer as to how the asbestos fibers

more

Determining and Prolonging Survival Rates In Mesothelioma

The average survival rate for mesothelioma after diagnosis is less than one year; however, certain individuals will survive longer than others, but the reason as to why this is, is largely unknown.  The latest study to be published in Histopathology investigates what it is in the body that determines a higher survival rate in some,

more

Mesothelioma Treatments Used Alongside Surgery – A Clinical Trial

Rare and aggressive in nature, mesothelioma is often a fatal cancer mainly due to its lack of response to most treatments. Surgical options have a higher chance of success for those in the early stages of the disease, but since there is a long latency period between asbestos exposure and symptoms of mesothelioma, often times

more

Improvements in Radiation Therapies Give More Treatment Options

When it comes to different treatments for mesothelioma patients, there is no shortage of diversity, as options include chemotherapy, radiation, surgery, immune-based therapies, gene-based therapies, and more. Chemotherapy treatments cisplatin and pemetrexed are first line treatments, especially among those who do not quality for surgery. Radiation treatment is available, but is typically the path less

more

Giving Cediranib Another Chance

A Phase I study for cediranib, a VEGFR/PDGFR kinase inhibitor, showed promising results in shrinking tumor size and increasing survival rates for those suffering from malignant pleural mesothelioma. This is not the first time cediranib has been studied as a possible treatment for mesothelioma. In 2011/2012 a Phase II trial for cediranib conducted by researchers

more

Pembrolizumab Update: Aduro Biotech Collaborates with Merck

A biopharmaceutical company named Aduro Biotech recently announced its collaboration with Merck to further evaluate the findings for the Phase II trial of KEYTRUDA ® (pembrolizumab) and to combine their own immunotherapy treatment, CRS-207. Information regarding KEYTRUDA ® treatment began to circulate late last year when data presented at the 17th World Conference on Lung

more

Bevacizumab (Avastin): Part of a New Treatment Regimen for Mesothelioma Patients

The results of a 2016 Phase III trial of the monoclonal antibody bevacizumab (Avastin) have established another option for treatment for those suffering from malignant pleural mesothelioma. Angiogenesis, which is the formation of new blood vessels, plays a key role in mesothelioma because it allows the tumors and cancer to spread. However, scientists and researchers

more

The Latest Clinical Trial for Nintedanib – Are You a Candidate?

Scientists and researchers are excited over the latest completion of a Phase II clinical trial for those suffering from mesothelioma – an incurable asbestos-caused cancer that has a median survival of only 9 to 12 months.  The LUME-Meso Phase II trial for patients with malignant pleural mesothelioma showed a slight increase in progression-free and overall

more

Ptac2S Potentially More Effective Than Cisplatin When Fighting Mesothelioma

Malignant Pleural Mesothelioma (MPM) is a rare, aggressive asbestos –related cancer that has a poor survival rate due to the fact that the cancer is hard to detect early, and once detected, has usually spread and is hard to control. Surgery is typically an effective option for removing cancerous cells, but in some cases, surgery

more

Last update: March 06, 2014. 08:41:31 pm.